Abstract
This article submitted to the journal CNS & Neurological Disorders - Drug Targets has been withdrawn upon the request of the author due to the errors and invalid information in the article.
Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.
The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php
BENTHAM SCIENCE DISCLAIMER:
It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.
CNS & Neurological Disorders - Drug Targets
Title:Withdrawal Notice: Comparison of Pharmaceutical Effect of Alemtuzumab and Natalizumab and Their Side Effects in Treatment of Various Stages of Multiple Sclerosis Patients
Volume: 20
Author(s): Mostafa Mohammadi*
Affiliation:
- Islamic Azad University of Central Tehran Branch, Department of Electrical Engineering, Tehran,Iran
Abstract: This article submitted to the journal CNS & Neurological Disorders - Drug Targets has been withdrawn upon the request of the author due to the errors and invalid information in the article.
Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.
The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php
BENTHAM SCIENCE DISCLAIMER:
It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.
Export Options
About this article
Cite this article as:
Mohammadi Mostafa*, Withdrawal Notice: Comparison of Pharmaceutical Effect of Alemtuzumab and Natalizumab and Their Side Effects in Treatment of Various Stages of Multiple Sclerosis Patients, CNS & Neurological Disorders - Drug Targets 2021; 20 () . https://dx.doi.org/10.2174/1871527320666210129121701
DOI https://dx.doi.org/10.2174/1871527320666210129121701 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Regulatory T Cells and Allergic Disease
Inflammation & Allergy - Drug Targets (Discontinued) Porphyrin Photosensitised Processes in the Prevention and Treatment of Water- and Vector-Borne Diseases
Current Medicinal Chemistry Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Current Drug Delivery Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry CC Chemokine Receptor Small Molecule Antagonists in the Treatment of Rheumatoid Arthritis and Other Diseases: A Current View
Current Topics in Medicinal Chemistry Delirium in Older Patients – A Review
Current Psychiatry Reviews Detection of the M. pneumonia in Synovial Fluid of Children with Negative Culture Arthritis: A Cross Sectional Study in Tehran, Iran
Infectious Disorders - Drug Targets Blood Brain Barrier in Hypoxic-Ischemic Conditions
Current Neurovascular Research Hypocholesterolemia
Current Vascular Pharmacology Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia
Current Neurovascular Research Emerging β-Amyloid Therapies for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Transgenic Mice as a Model for Alzheimers Disease
Current Alzheimer Research The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design CXCL8 as a Potential Therapeutic Target for HIV-Associated Neurocognitive Disorders
Current Drug Targets Regulation of Protective and Pathogenic Th17 Responses
Current Immunology Reviews (Discontinued) Designing Immunogens to Elicit Broadly Neutralizing Antibodies to the HIV-1 Envelope Glycoprotein
Current HIV Research Benzo[a]pyrene Toxicity and Inflammatory Disease
Current Rheumatology Reviews CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Mitochondrial Dysfunction in Huntington’s Disease: Pathogenesis and Therapeutic Opportunities
Current Drug Targets